You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences to Acquire YM BioSciences
Gilead Board Approves Two-for-One Stock Split
Gilead Sciences to Present at the NASDAQ OMX 29th Investor Program
European Commission Approves Viread® for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in Adolescents
Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients
Gilead’s Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients
Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients
Gilead Sciences to Present at the 2012 Credit Suisse Healthcare Conference on Wednesday, November 14
Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients
Gilead’s Once-Daily Novel Prodrug for the Treatment of HIV Meets 24-Week Primary Objective in Phase 2 Study
Gilead Sciences Announces Third Quarter 2012 Financial Results
Gilead Sciences to Release Third Quarter 2012 Financial Results on Tuesday, October 23, 2012
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Wednesday, September 19
Market Influences That Drive Equities Forward - Industry Report on Gilead Sciences, Inc. and Amgen Inc.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12
Gilead Sciences to Present at Baird’s 2012 Healthcare Conference on Thursday, September 6
A Refreshing Outlook - Consensus Reports on Gilead Sciences, Inc. and Amgen Inc.
U.S. FDA Approves Gilead’s Stribild™, a Complete Once-Daily Single Tablet Regimen for Treatment-Naïve Adults with HIV-1 Infection
Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries
Gilead Sciences Announces Second Quarter 2012 Financial Results
Gilead’s Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens
Gilead’s HIV Integrase Inhibitor Elvitegravir Dosed Once Daily as Effective as Twice-Daily Raltegravir Over Two Years of Therapy in Pivotal Phase 3 Study
Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study
Gilead Sciences to Release Second Quarter 2012 Financial Results on Thursday, July 26, 2012
U.S. Food and Drug Administration Approves Gilead’s Truvada® for Reducing the Risk of Acquiring HIV
Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat
Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients
European Medicines Agency Validates Gilead’s Marketing Application for Elvitegravir for Treatment of HIV Infection
Gilead Sciences to Present at the 32nd Annual William Blair & Company Growth Stock Conference on Wednesday, June 13
Gilead Sciences Appoints Two New Members to Health Policy Advisory Board
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Files European Marketing Application for Boosting Agent Cobicistat
FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV
FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV
Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16
Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia
Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8
Gilead Sciences Announces First Quarter 2012 Financial Results
Gilead Sciences to Release First Quarter 2012 Financial Results on Thursday, April 26, 2012
Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Na ïve Hepatitis C Patients
Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients
Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients
Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week
Data Show Gilead’s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study
Gilead’s Quad Single Tablet Regimen for HIV Non-Inferior to Atripla® in Pivotal Phase 3 Study
Gilead Sciences Quad Study 102 Results Conference Call on Wednesday, March 7, 2012
Gilead Sciences to Present at the Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13
Gilead Sciences to Present at the Cowen & Company 32nd Annual Health Care Conference on Wednesday, March 7
Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study
U.S. FDA Grants Priority Review for Truvada® for Reducing the Risk of Acquiring HIV Infection
Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2011 Financial Results on Thursday, February 2, 2012
Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV
U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV
Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics
Gilead Sciences Completes Acquisition of Pharmasset, Inc.
Gilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc.
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Gilead Sciences to Present at the 30th Annual JPMorgan Healthcare Conference on Monday, January 9
2012 Interactive Annual Report